An alternating magnetic field (AMF)-responsive controlled release system has been developed by the binding of mono-6-deoxy-6-(p-tolylsulfonyl)-β-cyclodextrin (βCD-Ts) onto amine-modified superparamagnetic iron oxide nanoparticles (MNP-NH 2 ), resulting in a MNP-βCD nanocarrier.
No takes yet. Share an insight, caveat, or question.
Santos et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: